Next-Generation Sequencing Market: Current Analysis and Forecast (2021 - 2027)

Next-Generation Sequencing Market: Current Analysis and Forecast (2021 - 2027)

  • UnivDatos Market Insight
  • July 2021
  • Healthcare
  • 162 pages

Report Description

Next-generation sequencing (NGS) is a technology used to determine the RNA or DNA sequence to study genetic variation associated with various types of diseases or other biological phenomena. This method was introduced for commercial use in 2005 and was initially known as massively-parallel sequencing as it enables the sequencing of several DNA strands at the same time. NGS provides the ideal throughput per run, and studies can be performed quickly and cost-effectively

NGS is of extreme importance to medical practice as it provides a definitive diagnosis for many clinically heterogeneous diseases. Consequently, it enables a more precise disease prognosis and provides guidance towards the selection of the best therapeutic choices for the affected patients. Much of its current promise comes from its ability to examine the human genome at various stages, from chromosome to single-base changes

The NGS market is growing exponentially on account of growing advancements in NGS technology, rising cancer incidences and increasing applications of NGS in various sectors. Further, the study of genomics is attracting attention from investors as well as from the public as it impacts the very core of lives and all living things around the globe. Completing the sequencing of the first human genome in 2003 was a key breakthrough that took over 10 years and cost approximately USD 3 billion. Since then, the sequencing speed of a genome has more than doubled, significantly outpacing Moore's Law. Today’s high throughput sequencing machines process the human genome in a matter of hours at a cost approaching USD 1,000. These advancements have allowed researchers to analyze the genome in less time, greatly increasing the pace of scientific discovery

Based on product/services, the market is fragmented into consumables, platforms, services, and bioinformatics. The consumables segment generated revenue of USD XX million in 2020. The market is expected to grow at a CAGR of XX% during the forecast period to reach a market valuation of USD XX million by 2027F owing to the increasing demand of the reagents and other consumables used for preparation of sample for sequencing of the genomes

Based on technology, the market is bifurcated into SBS, SMRT, pyrosequencing, Ion semiconductor sequencing, nanopore sequencing and others. The SBS segment generated revenue of USD XX million in 2020. The market is expected to grow at a CAGR of XX% during the forecast period to reach a market valuation of USD XX million by 2027F as it one of the most widely adopted NGS technology globally

Based on the application, the market is fragmented into biomarkers & cancer, diagnostics, drug discovery, personalized medicine, agriculture & animal research, and others. The biomarker segment dominated the market and generated revenue of USD XX million in 2020. However, personalized medicine is anticipated to grow at highest CAGR during the forecast period and reach USD XX million by 2027F

The next-generation sequencing research and development and utilization are available at various centers including pharma companies, biotechnology companies, academic & government research institutes, clinical research, and others. The academic & government research institute segment is anticipated to dominate the market during the analyzed period and reach USD XX million by 2027F Owing to the growing number of collaborations among major key industry players and academic & government research institutes

For a better understanding of the market adoption of the next-generation sequencing market, the market is analyzed based on its worldwide presence in the countries such as North America (United States and Canada), Europe (Germany, France, Italy, Spain, United Kingdom and Rest of Europe), Asia-Pacific (China, Japan, India, and Rest of APAC), and Rest of World. North America constitutes a major market for the next-generation sequencing industry and generated revenue of USD XX million in 2020 owing to the increasing incidence of cancer and other diseases, rising healthcare spending, and increasing government initiatives in the region

Some of the major players operating in the market include Illumina, Thermo Fisher Scientific, QIAGEN, Agilent Technologies, Bio-Rad Laboratories, F. Hoffmann-La Roche, BGI, Oxford Nanopore Technologies, PerkinElmer, Eurofins Scientific, etc. Several M&A’s along with partnerships have been undertaken by these players to develop new and advanced NGS platforms

Global Next-generation Sequencing Market was valued at US$ XX billion in 2020 and is anticipated to reach US$ XX billion by 2027 displaying an elevated CAGR of XX% over the forecast period (2021-2027). Next-generation sequencing (NGS) is a technology used to determine the RNA or DNA sequence to study genetic variation associated with various types of diseases or other biological phenomena. This method was introduced for commercial use in 2005 and was initially known as massively-parallel sequencing as it enables the sequencing of several DNA strands at the same time. NGS provides the ideal throughput per run, and studies can be performed quickly and cost-effectively.

The NGS market is growing exponentially on account of rapid advancements in NGS technology, rising cancer incidences, and increasing applications of NGS in various sectors. Further, the study of genomics is attracting attention from investors as well as from the public as it impacts the very core of lives and all living things around the globe. Completing the sequencing of the first human genome in 2003 was a key breakthrough that took over 10 years and cost approximately USD 3 billion. Since then, the sequencing speed of a genome has more than doubled, significantly outpacing Moore's Law. Today’s high throughput sequencing machines process the human genome in a matter of hours at a cost approaching USD 1,000. These advancements have allowed researchers to analyze the genome in less time, greatly increasing the pace of scientific discovery

Furthermore, the rise in cancer incidences and reduced sequencing costs is anticipated to boost the market growth. The cost of whole-genome sequencing has dropped promptly over the last decade with the emergence of next-generation sequencing. Additionally, the increasing government-funded initiatives are further propelling the growth of the NGS market across the globe. For instance, recently in 2020, the Department of Biotechnology (DBT) initiated the ambitious “Genome India Project” (GIP) to collect 10,000 genetic samples of citizens across India to build a reference genome. The precision health, rare genetic disorders, mutation spectrum of genetic and complex diseases in the Indian population, genetic epidemiology of multifactorial lifestyle diseases, and translational research are some of the priority areas of this project.

Illumina, Thermo Fisher Scientific, QIAGEN, Agilent Technologies, Bio-Rad Laboratories, F. Hoffmann-La Roche, BGI, Oxford Nanopore Technologies, PerkinElmer, and Eurofins Scientific are some of the prominent players operating in the global next-generation sequencing market. Several M&A’s along with partnerships have been undertaken by these players to by these players to develop new and advanced NGS platforms.

Insights Presented in the Report

“Amongst product/services, consumables segment holds the major share”

Based on the product/services type, the market is fragmented into consumables, systems & software, and services. The consumables segment dominated the market with a share of XX% in 2020 and is expected to maintain its dominance during the forecast period owing to the increasing number of sequencing procedures worldwide. However, the services segment is also expected to grow at the highest CAGR of XX% during the projected timeframe to reach market valuation at USD XX million by 2027. The growth of this segment is attributed to the growing adoption of NGS-based diagnostics and the need for better data management services for storing a huge amount of generated data

“Amongst technology, SBS dominated the market in 2020”

Based on technology, the market is fragmented into SBS, SMRT, pyrosequencing, Ion semiconductor sequencing, nanopore sequencing, and others. The SBS segment generated revenue of USD XX million in 2020. The market is expected to grow at a CAGR of XX% during the forecast period to reach a market valuation of USD XX million by 2027F. This segment is expected to grow as Illumina sequencing technology, sequencing by synthesis (SBS) is widely adopted NGS technology across the world. For instance, SBS technology is responsible for generating more than 90% of the world’s sequencing data. Further, the increase in the availability of NGS platforms based on SBS is driving the growth of the segment

“Amongst application, Biomarkers & Cancer is anticipated to grow at the highest CAGR during the analyzed period”

Based on application, the market is fragmented into diagnostics, biomarkers & cancer, drug discovery, personalized medicine, agriculture & animal research, and others. The biomarkers & cancer segment generated revenue of USD XX million in 2020. The market is expected to grow at a CAGR of XX% during the forecast period to reach a market valuation of USD XX  million by 2027F owing to the rising incidences of cancer all over the world. However, the personalized medicine segment is expected to grow at the highest CAGR of XX% between 2021-2027F as many researchers are focusing on identifying & monitoring different biomarkers that can be later used for developing efficient personalized medicine. For instance, as per the recent study published in July 2020, scientists are developing a multi-analyte test strip that can be used for monitoring even the slightest change in the biomarker profile of a patient. This technology will combine big-data analytics and advanced technologies such as wearables for ensuring the continuous acquisition of precise data.

Amongst end-user, academic & government research institutes segment holds the major share”

Based on end-users, the market is fragmented into pharma companies, biotechnology companies, academic & government institutes, clinical research, and others. The academic & government research institutes segment generated revenue of USD XX million in 2020. The market is expected to grow at a CAGR of XX% during the forecast period to reach a market valuation of USD XX million by 2027F owing to the growing number of collaborations between key industry players of NGS and academic research institutes. For instance, in 2019, Illumina and the Broad Institute of MIT and Harvard collaborated for the co-development of secondary genomic analysis algorithms and software.

“North America signifies one of the largest markets of next-generation sequencing Market”

For a better understanding of the market dynamics of the next-generation sequencing market, a detailed analysis was conducted for different regions across the globe including North America (United States, Canada, and the Rest of North America), Europe (Germany, France, Italy, Spain, United Kingdom and Rest of Europe), Asia-Pacific (China, Japan, India, and Rest of APAC), Rest of World has been conducted. North America dominated the market and generated revenue of USD XX million in 2020 owing to the increasing cancer incidence and higher government-funded initiatives. At the same time, Asia-Pacific is anticipated to grow at the highest CAGR of XX% during the forecast period.

Reasons to buy this report:

  • The study includes market sizing and forecasting analysis validated by authenticated key industry experts
  • The report presents a quick review of overall industry performance at one glance
  • The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolio, expansion strategies, and recent developments
  • Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry
  • The study comprehensively covers the market across different segments
  • Deep dive regional level analysis of the industry

Customization Options:

The next-generation sequencing market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.

Companies Covered

  • Illumina
  • Thermo Fisher Scientific
  • QIAGEN
  • Agilent Technologies
  • Bio-Rad Laboratories
  • F. Hoffmann-La Roche
  • BGI
  • Oxford Nanopore Technologies
  • PerkinElmer
  • Eurofins Scientific

Have query on this report?

Make an Enquiry

Table of Content

1 MARKET INTRODUCTION
1.1 Market Definitions
1.2 Objective of the Study
1.3 Limitation
1.4 Stake Holders
1.5 Currency Used in Report
1.6 Scope of the Global Next-generation Sequencing Market Study

2 RESEARCH METHODOLOGY OR ASSUMPTION
2.1 Research Methodology for the Global Next-generation Sequencing  Market
2.1.1 Main Objective of the Global Next-generation Sequencing  Market

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 COVID-19 IMPACT

6 GLOBAL NEXT-GENERATION SEQUENCING MARKET REVENUE

7 MARKET INSIGHTS BY PRODUCT/SERVICES

7.1 Consumables
7.2 Platforms
7.3 Services
7.4 Bioinformatics

8 MARKET INSIGHTS BY TECHNOLOGY
8.1 SBS
8.2 SMRT
8.3 Pyrosequencing
8.4 Ion Semiconductor Sequencing
8.5 Nanopore Sequencing
8.6 Others

9 MARKET INSIGHTS BY APPLICATION
9.1 Biomarkers & Cancer
9.2 Diagnostics
9.3 Drug Discovery
9.4 Personalized Medicine
9.5 Agriculture & Animal Research
9.6 Others

10 MARKET INSIGHTS BY END-USERS
10.1 Pharma Companies
10.2 Biotechnology Companies
10.3 Academic & Government Research Institutes
10.4 Clinical Research
10.5 Others

11 MARKET INSIGHTS BY REGION
11.1 NORTH AMERICA NEXT-GENERATION SEQUENCING MARKET
11.1.1 United States
11.1.2 Canada
11.1.3 Rest of North America
11.2 EUROPE NEXT-GENERATION SEQUENCING MARKET
11.2.1 Germany
11.2.2 France
11.2.3 United Kingdom
11.2.4 Spain
11.2.5 Italy
11.2.6 Rest of Europe
11.3 ASIA PACIFIC NEXT-GENERATION SEQUENCING MARKET
11.3.1 China
11.3.2 Japan
11.3.3 India
11.3.4 Australia
11.3.5 Rest of Asia Pacific
11.4 REST OF THE WORLD NEXT-GENERATION SEQUENCING  MARKET

12 NEXT-GENERATION SEQUENCING MARKET DYNAMICS
12.1 Market Drivers
12.2 Market Challenges
12.3 Impact Analysis

13 NEXT-GENERATION SEQUENCING MARKET OPPORTUNITIES

14 NEXT-GENERATION SEQUENCING MARKET TRENDS & INSIGHTS

15 LEGAL & REGULATORY FRAMEWORK

16 DEMAND AND SUPPLY SIDE ANALYSIS

16.1 Demand Side Analysis
16.2 Supply Side Analysis
16.2.1 Top Product Launches
16.2.2 Top Business Partnerships
16.2.3 Top Merger & Acquisitions

17 VALUE CHAIN ANALYSIS

18 COMPETITIVE SCENARIO

18.1 Porter’s Five forces analysis
18.1.1 Bargaining power of Supplier
18.1.2 Bargaining power of Buyer
18.1.3 Industry Rivalry
18.1.4 Availability of Substitute
18.1.5 Threat of new Entrants

19 COMPANY PROFILED
19.1 Bio-rad Laboratories
19.1.1 Key Facts
19.1.2 Business Description
19.1.3 Key Product/Services Offerings
19.1.4 Growth Strategy
19.1.5 SWOT Analysis
19.1.6 Key Financials
19.1.6.1 Revenue Split
19.1.6.2 Financial Overview of Bio-rad Laboratories
19.1.7 Recent Developments
19.1.7.1 Product Launch
19.1.7.2 Partnerships
19.1.7.3 Business Expansion and Investments
19.1.7.4 Merger and Acquisition
19.2 Agilent Technologies
19.3 Illumina, Inc.
19.4 Thermo Fisher Scientific
19.5 F. Hoffmann-La Roche
19.6 Oxford Nanopore Technologies
19.7 Qiagen
19.8 BGI
19.9 PerkinElmer
19.10 Eurofins Scientific

20 DISCLAIMER

Success Stories

Our Clients